KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
发明人:
KWON, Ki Sun,권기선,KIM, Seon-Young,김선영,CHOI, So Young,최소영,DHO, So Hee,도소희,PARK, Sung Sup,박성섭,LEE, Kwang Pyo,이광표
申请号:
KRKR2012/001316
公开号:
WO2012/115437A2
申请日:
2012.02.21
申请国别(地区):
WO
年份:
2012
代理人:
摘要:
The present invention relates to the pharmaceutical composition for cancer treatment or metastasis inhibition containing expression or activation inhibitors of MAP7D2 protein as an active ingredient. More specifically a novel anti-cancer therapeutic target has been discovered using data-mining techniques by building a large-scale gene expression database of human cancer tissues, and, based on the gene expression profiles of cancer cell lines, appropriate cancer cell lines were selected and experimentally verified through the inhibition of candidate target genes. Through these, MAP7D2 has been verified as a novel potential anti-cancer target which is over-expressed in a variety of cancer tissues or cells, such as cancer tissues or cells of the kidney, lung, large-intestine, ovary, stomach and liver, and inhibition of which impedes the growth, movement, infiltration and metastasis of cancer cells, thereby leading to cell destruction. As such, expression levels of MAP7D2 can be useful as a diagnostic marker for cancer and an MAP7D2 protein expression or activation inhibitor can be used as an active ingredient in a pharmaceutical composition for cancer treatment or metastasis inhibition.La présente invention concerne une composition pharmaceutique destinée au traitement du cancer ou à linhibition des métastases, contenant des inhibiteurs de lexpression ou de lactivation de la protéine MAP7D2 en tant que principes actifs. Plus spécifiquement, une nouvelle cible thérapeutique anticancéreuse a été découverte au moyen de techniques dexploration de données, par la construction dune base de données dexpression génétique à grande échelle de tissus cancéreux humains sur la base des profils de lexpression génétique de lignées cellulaires cancéreuses, des lignées cellulaires cancéreuses appropriées ont été choisies et vérifiées expérimentalement par linhibition de gènes cibles candidats. Ceci a permis de confirmer que la MAP7D2 constituait une nouvelle cible anticancéreuse poten